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Division of Rheumatology and Early Arthritis Clinic, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy
Rheumatoid arthritis (RA) is a highly heterogeneous syndrome in terms of clinical
presentation, progression, and response to therapy. In such a complicated context, the
identification of disease-related biomarkers would be undoubtedly helpful in assisting
tailored approaches for every patient. Despite remarkable efforts, however, progress
in new biomarker development and validation is dramatically slow. At present, none
of the candidate genetic, cellular, or molecular biomarker has yet surpassed the
clinical value of RA-specific autoantibodies, including rheumatoid factor (RF) and
anti-citrullinated protein autoantibodies (ACPA). Rather, recent years have witnessed
significant advancements in our understanding of the multiple roles that RF and ACPA
play in RA pathophysiology. This has helped clarifying the mechanistic basis of the clinical
associations of autoantibodies in RA. In this short review, we will briefly summarize
the effector functions of RF and ACPA, and analyse how autoantibodies may help
subclassifying RA patients in terms of clinical presentation and response to therapy.
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Our knowledge on rheumatoid arthritis (RA) has dramatically increased over the past 2 decades.
Recognition that RA starts early and key processes of damage even develop before clinically
apparent arthritis have fuelled the processes of early diagnosis and prompt treatment institution
within the window of opportunity (1, 2). In parallel, better understanding of disease pathogenesis
has helped developing new targeted therapeutics that allow good control of signs and symptoms
and improve the overall outcomes of the disease (3). Despite these remarkable advances, however,
the management of patients with RA remains imprecise. It is widely accepted that RA encompasses
great heterogeneity in clinical presentation and outcomes. Yet, any attempt of personalizing
treatment based on patients’ genotypic and phenotypic characteristics has been largely unsuccessful
(4, 5). Despite considerable efforts in producing new taxonomies, the most robust distinction
of RA subtypes remains the classification based on the autoantibody status. Patients with
rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) have specific genetic
and environmental risk factors, and differ from autoantibody-negatives in their clinical course
and prognosis (6). The recent discovery of the direct pathogenetic roles of autoantibodies in RA
(7) has refueled the possibility of using specific characteristics of the RF and ACPA response as
clinically useful biomarkers. In this short review, we will try to summarize the clinical associations
of autoantibodies in RA also in light of their mechanistic contribution to disease processes.
THE PATHOGENIC ROLE OF AUTOANTIBODIES IN RA
The past 10 years of research have shed increasing and exciting light on the multiple roles of
autoantibodies (both RF and ACPA) in RA pathology, briefly summarized below.
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Pro-inflammatory Role
All immunoglobulins (Ig), and in particular those of the IgG
class, have effector functions mediated by the interaction of
their Fc tail with specific activating or inhibitory receptors
(FcR) present on the surface of various cell types. ACPA
detected by second-generation assays are mostly of the IgG class,
with predominance of the IgG1 subclass (8), which mediates
Ig immunological activities (9). Through this mechanism,
immune complexes containing ACPA are able to stimulate
tumor necrosis factor (TNF) secretion by macrophages (10–12)
(Figure 1A). This stimulus appears to be increased by the
simultaneous presence of RF of the IgM and IgA classes,
suggesting a synergism between ACPA and RF (12–14). In
addition to FcR-mediated cell activation, ACPA can directly
activate monocytes by binding through their Fab variable
portion to a citrullinated GRP78 cell-surface receptor, driving
NF-κB activation, and cytokine production (15) (Figure 1A).
Another important effector function of Ig is represented by
their ability to activate complement via both the classical
and the alternative pathway. Complement activation is also
demonstrated for ACPA (16), but is particularly effective in
the case of the classic pentameric IgM RF (17). Accordingly,
early studies have shown that aggregates of IgG-RF within
the joints are associated with low complement levels and low
C1q and C3 in synovial fluid (18). More recently, ACPA
have been shown to influence inflammation and its chronicity
also by increasing the generation of neutrophil extracellular
traps (NETs) (19). NETs then stimulate joint inflammation
by promoting the production of pro-inflammatory cytokines,
chemokines, and adhesion molecules by synovial fibroblasts
(19, 20).
Most of the pathological functions of autoantibodies in
course of disease have been traditionally attributed to IgGs
(macrophage activation through FcγR engagement) and IgMs
(complement activation). However, recent evidence has also
highlighted important effector functions of antibodies of the
IgA class. Indeed, IgA potently activate neutrophils (21), and
incubation of RA neutrophils with IgA immune complexes
results in the release of NETs (22). These in vitro effects
fit with clinical evidences linking the presence of IgA RF
to worse disease prognosis (23, 24), and provide intriguing
support to the possible mucosal origin of autoantibody
responses in RA. Indeed, IgA represents the dominant Ig
class in mucosal immune responses, and IgA plasmablasts
dominate in ACPA-positive individuals at risk of developing
RA (25).
Importantly, the unique effectors functions of autoantibodies
are not only mediated by their diversification in classes and
subclasses, but also by some specific biochemical characteristics
including the sugar moiety attached to the Fc tail (26). In
particular, antibodies carrying Fc glycans that lack galactose
residues display an increased ability to activate the immune
system (27, 28). Interestingly, a decrease in the level of
galactosylation is one of the most prominent changes in total
serum and ACPA IgG in course of RA (29, 30), whilst levels
of anti-inflammatory glycans rise during drug-induced disease
remission and pregnancy (31–33).
Altogether, the afore described mechanisms underline the
complexity of the inflammatory function of autoantibodies in
RA, which depends on intricate and not completely disentangled
characteristics including classes, subclasses and biochemical
properties. Better understanding of ACPA and RF diversity across
the different phases of the disease will hopefully allow important
advancements in the biological and clinical understanding of how
inflammation develops, evolves and eventually resolves in RA.
Osteoclastogenesis
The epidemiological association between ACPA and the severity
of radiographic damage in RA has recently found causal
explanation with the identification of the direct osteoclastogenic
role of ACPA (34, 35). In general, immune complexes containing
IgG, particularly those which have undergone modifications of
their glycan residues, are able to bind to activating FcγR present
on the surface of immature and mature osteoclasts and promote
their activation (36–38) (Figure 1B). In addition, through their
Fab portion, ACPA are able to bind to citrullinated vimentin
present on the surface of osteoclasts and their monocyte-
macrophage precursors (39), stimulating their differentiation
and activation through interleukin (IL)-8 mediated circuits (40)
(Figure 1B). Again, the process of ACPA-induced osteoclast
activation seems to be amplified by the concomitant presence
of RF, as indirectly suggested by radiographic studies which
have shown increased amounts of joint and systemic bone loss
in patients with double autoantibody-positivity, especially at
high titres (41, 42). Altogether, such novel insights into the
osteoclastogenic properties of ACPA have thus reinforced earlier
concepts on the pathophysiological role of autoantibodies in RA
by demonstrating their direct involvement in specific process of
the disease such as bone damage.
Nociception
Besides triggering inflammation and enhancing bone damage, a
direct role of ACPA in promoting pain has also been suggested.
Indeed, at least in experimental mouse models, the inoculation
of ACPA triggers a pain reaction. Such mechanism seems to
be mediated by the binding of ACPA to citrullinated epitopes
on the surface of marrow osteoclast precursors, inducing the
expression of CXCL1 (which is the murine analog of human
IL-8), which in turn promotes nociceptive mechanisms (43).
Although the nociceptive effect of ACPA in vivo remains to
be fully proven, clinical evidences showing that ACPA-positive
subjects may suffer from joint pain in the absence of overt
synovitis (44) offer intriguing confirmation of this concept.
AUTOANTIBODIES AND CLINICAL
PHENOTYPE
It is now well-established that autoantibodies precede the onset
of clinical symptoms by several years in a proportion of patients
with RA (45, 46). The autoantibody response significantly evolves
in the pre-clinical phase of the disease, with level increase,
epitope spreading, isotype switching, affinity maturation, and
change in glycosylation over time (47). Although the precise
dynamics of such changes are not properly defined, and are
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FIGURE 1 | Pro-inflammatory and osteoclastogenic roles of autoantibodies in rheumatoid arthritis. The multiple effects of anti-citrullinated protein antibodies (ACPA)
and rheumatoid factor (RF) on macrophages (A) and osteoclasts (B) are shown. Collectively, ACPA are able to stimulate cytokine production by macrophages both
through the interaction of their Fc tail with stimulating Fcγ receptors, and through Fab-mediated recognition of membrane citrullinated proteins such as GRP78.
Pentameric class M RF potentiates ACPA-induced inflammation likely via activation of the complement cascade (A). ACPA are also able to promote osteoclast
differentiation and activation through similar mechanisms mediated by their Fc and Fab portions. Again, clinical studies indicate that RF, especially at high titres,
amplifies ACPA-mediate bone damage (B).
likely to vary among different subjects, there is evidence that
the extent of the autoantibody response conditions some clinical
characteristics also in the very early phases of RA. Indeed,
among autoantibody-positive subjects suffering from arthralgia,
those at higher risk of quickly developing RA generally have
higher autoantibody levels (48), more epitope spreading (49),
and more frequently are ACPA and RF double positive (50).
Thus, in a broader sense, autoantibody diversification may
have an amplifying effect on inflammation and autoimmunity,
leading to the transition from asymptomatic autoimmunity to
complex responses triggering clinical inflammation. If this is
the case, changes in autoantibody characteristics may serve
as useful biomarkers to predict the development of RA
and may represent valuable targets for preventive therapeutic
strategies.
If early, pre-clinical autoimmunity remains an area of
investigation, the clinical associations of autoantibodies in course
of established RA have been abundantly analyzed. Literature
dating back to the’80 was overall concordant in associating RF
positivity, especially at high titers, to more inflammation (51, 52).
As such, fluctuations in RF levels were proposed as a biomarker
of disease activity and response to therapy (53). Also, RF of the
IgA class was regarded as a specific diagnostic marker in early
arthritis (54) and, in general, as a marker of more aggressive
and refractory disease (23, 24). With ACPA capturing the scene
from the 2000s, studies on early RA populations have massively
focussed on this new autoantibody system, and interest on RF
as a possible serological marker of inflammation has temporarily
declined. In spite of their well-established association with more
erosive disease, however, ACPA have soon appeared scarcely
informative for patients’ clinical phenotyping at presentation.
In early RA patients from the Leiden early arthritis cohort,
van der Helm-van Mil and co-authors (55) indeed reported
similar symptoms and joint distribution between ACPA-positive
and -negative patients. Number of swollen and tender joints,
pain, functional status and acute phase reactants also appeared
unaffected by the ACPA status in early RA patients from a
Swedish cohort (56). Similarly, in 92 RA patients with symptoms
of <3 months’ duration, the number of affected joints and
inflammatory markers were comparable, and the only observed
difference was the prevalence of knee involvement, slightly
more common in ACPA-positive patients (57). More recent
analyses have however relooked at clinical associations taking
into account the interactions between RF and ACPA, rather
than the two autoantibodies separately. In this setting, double
autoantibody-positive patients seem to be characterized by a
more inflammatory phenotype. In the French ESPOIR cohort,
ACPA and RF double-positive patients presented with more
marked elevation of acute phase reactants (58). Similarly, a large
US study of 1,488 RA patients showed that double positivity
for RF and ACPA was associated with significantly higher
levels of C-reactive protein and pro-inflammatory cytokines
(12). This was consistent with the amplifying effect of RF on
TNF production triggered by ACPA in vitro (12). Analyzing
the clinical data of patients enrolled in several clinical trials,
Aletaha and collaborators (59) confirmed the boosting activity
of RF on the background of ACPA, as ACPA single-positive
patients had lower levels of disease activity. More recently,
Derksen et al. (60) have nicely demonstrated in two large
independent early RA cohorts that the amount of inflammation
is proportional to the number of autoantibody-specificities, as
patients with RF, ACPA and anti-carbamylated protein antibodies
all positive had the highest levels of acute phase reactants. If
these findings are confirmed, the simple distinction between
autoantibody-positive and -negative patients would therefore
appear insufficient at capturing different aspects of the disease.
Rather, within autoantibody-positive patients, differences might
exist depending on the diversity of the autoimmune response,
as broader responses (indicating a break of tolerance to more
autoantigens) would harbor more severe clinical phenotypes. It
is however important to emphasize that the clinical association
between the extent of the autoimmune response and disease
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activity described here does not allow to draw any conclusion
on the cause-effect relationship between autoantibodies, in
particular RF, and inflammation. On the one hand, the classic
IgM RF could indeed represent a pro-inflammatory trigger, in
light of its ability to activate complement (17, 18). On the other
hand, RF production could be boosted by innate inflammatory
stimuli outside a T cell-dependent germinal center reaction
(61), therefore representing consequence rather than cause of
inflammation.
Another aspect of the disease which appears to be strongly
(and possibly mechanistically) linked to the presence of
autoantibodies is extra-articular involvement, including
cardiovascular (CV) comorbidity. Several studies have reported
higher rates of CV mortality and events in autoantibody-
positive patients (62, 63). This could be attributed to the higher
inflammatory burden associated to autoantibodies, contributing
to accelerated atherosclerosis, endothelial dysfunction, and
plaque vulnerability (64). Supporting their direct pathogenic
role, autoantibodies have been associated with CV events even
in the absence of clinically apparent RA (65, 66). Indeed,
irrespective of inflammation, autoantibodies might affect cardiac
function, as suggested by studies indicating left ventricular strain,
impaired left ventricular relaxation, and lower left ventricular
mass in association with ACPA (67, 68). The direct effects of
ACPA are in line with large epidemiological studies showing
an increased rate of CV deaths specifically in ACPA-positive
RA patients, whilst RF would be more associated to non-CV
mortality (63).
It is however important to note here that the aforementioned
associations between autoantibody diversity and local and
systemic inflammation refer to patients fulfilling the 1987
classification criteria for RA. There is ample evidence now
indicating that the introduction of the 2010 classification criteria
has profoundly changed the clinical picture of RA (69). In
this new setting, the high weigh attributed to autoantibodies
in the scoring system has produced the paradoxical effect
of making the clinical presentation of autoantibody-positive
patients significantly milder compared to autoantibody-negatives
(70, 71). Accordingly, ACPA-positive patients diagnosed with the
2010 criteria do not show more severe disease burden in terms of
fatigue, pain, well-being, and independence compared to ACPA-
negative patients (72). Also, with decreasing rates of incident
CVD, the association between autoantibodies and comorbidities
tends to disappear (73).
AUTOANTIBODIES AND DISEASE
REMISSION
Disease remission is increasingly achievable in patients with
RA provided that diagnosis is established early and treatment
instituted effectively (74). However, the definition of remission is
challenging, as it also incorporates the concepts of sustainability
on treatment as well as persistence after drug suspension (75, 76).
In this context, the predictive value of autoantibodies is difficult
to establish. Furthermore, RF and ACPA could be related to
slightly different remission outcomes.
In historical RA cohorts, RF has been shown to be inversely
associated with the achievement of point remission in several
studies. In the Utrecht RA cohort established in 1990, 36% of
the patients achieved at least one period of remission; among
other predictors, RF negativity was associated with 1.63 hazards
of achieving remission (77). IgM RF positive patients were less
likely to achieve remission also in other cohorts (78, 79), and
a recent study on early RA patients commencing methotrexate
(MTX) as their first disease modifying anti-rheumatic drug
(DMARD) within 3 months of their baseline visit confirmed that
RF was associated with earlier MTX failure due to inefficacy
(80). In contrast, the predictive value of ACPA for achieving
point remission is not that obvious. Surprisingly, studies in
early RA cohorts diagnosed according to the 2010 classification
criteria have shown that ACPA might rather be regarded as
a marker of better outcomes, as ACPA-positive patients more
frequently achieve remission upon induction therapy with high
doses of MTX (81). Furthermore, broader autoantibody profiles
in terms of specificities and classes associate with earlier response
to treatment (82). Whether such findings also depend on
the lower levels of disease activity in ACPA-positive patients
diagnosed according to the 2010 criteria (70) remains to be
demonstrated.
RF positivity not only appears associated with lower rates of
point remission, but also with reduced chances of maintaining
the state of disease remission over time. In a population of 650 RA
patients followed for a mean of 10.3 years, Raheel et al. (83) were
able to demonstrate that patients with positive RF had higher
rates of flare compared to RF-negatives. In the IMPROVED
study, positivity for RF was confirmed to be predictive of losing
remission in course of drug tapering (84). Interestingly enough,
in the same study, ACPA did not show a similar association,
as ACPA-positive patients achieving early remission could taper
medications similarly to ACPA-negatives (84). Very recently,
data on the ARCTIC trial, in which treatment adjustments were
tightly targeted on disease remission, have confirmed that RF, but
not ACPA positivity was associated with not reaching sustained
remission in univariate analysis (85).
If ACPA thus appear rather ininfluent in the achievement and
maintenance of remission on treatment, their role in predicting
disease relapse after drug suspension is undoubtedly established.
In the Leiden Early Arthritis Clinic and the British Early
Rheumatoid Arthritis Study, sustained DMARD-free remission
was achieved far less commonly by ACPA-positive patients (86).
Similar results were confirmed in the context of clinical trials
(87), including again the IMPROVED study in which ACPA-
positive patients showed more relapses in disease activity soon
after drug suspension (84). This findings have solid evidence also
in the recent RETRO trial (88–90). Here, ACPA-positivity and
broader ACPA reactivities emerged as the strongest predictors of
disease recurrence independent of the level of residual disease
activity at drug tapering/discontinuation. Importantly, ACPA
appear associated to increased hazards of losing remission
irrespective of the type of drug being suspended, as studies
on TNF and non-TNF drug tapering have shown similar
results compared with conventional synthetic (cs) DMARD
suspension (91).
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Collectively, data from the literature thus indicate that both
RF and ACPA are important factors related to remission
outcomes. RF would mostly predict lower chances of
achieving and maintaining remission on treatment, whilst
ACPA would represent the major obstacle for safe drug
suspension.
AUTOANTIBODIES AND RESPONSE TO
THERAPY
Response to Conventional Synthetic
DMARDs
Despite being unanimously considered as important prognostic
markers associated with more rapid evolution of joint damage,
RA-specific autoantibodies, and in particular ACPA, have never
been recommended as a guidance to assist the choice of first-line
treatment in patients with early RA. Indeed, both the European
and the American recommendations push for MTX as the
anchor drug in all patients irrespective of autoantibody positivity
(74, 92). This recommendation funds on evidences indicating
that the worse radiographic progression observed in ACPA-
positive RA is not a consequence of continuing disease activity,
as response to therapy seems overall comparable irrespective of
the serological subgroup. Among the several studies published
so far, the more robust evidence of this concept probably
comes from the long-term follow-up of the BEST strategy
trial (93). Here, despite more radiological damage progression,
ACPA-positive patients achieved reduction in disease activity
similar to that of ACPA-negative patients in all treatment
groups. Similarly, in the METEOR database including more
than 1,800 patients with MTX as part of their initial treatment
strategy, short-term remission in newly diagnosed RA was
not affected by neither ACPA nor RF positivity (94). The
analysis of ACPA reactivities does not seem to add much to
prediction of treatment response, as recently shown in the
context of the ARCTIC trial, were no difference in median
baseline levels or number of ACPA reactivities was found
between patients with different EULAR responses to MTX
monotherapy (95).
If MTX efficacy appears overall similar between autoantibody-
positive and –negative patients, still some differences in
the magnitude of the response according to the serological
status might exist. In patients with undifferentiated arthritis
according to the 1987 criteria, MTX was effective at delaying
progression to RA only in ACPA-positive patients, many of
whom could be reclassified as having had RA according to the
2010 criteria at baseline (96). Similarly, in the IMPROVED
study, ACPA-positivity was associated with higher chances
of achieving remission upon induction treatment with MTX
at the dose of 25 mg/week (81). In line with these data,
results from our early arthritis inception cohort indicate
that higher starting doses of MTX (15 mg/week) are more
effective than lower doses (10 mg/week) in autoantibody-
positive but not autoantibody-negative patients (97). The
differential response to more aggressive strategies with
csDMARDs also emerges from the CARDERA trial (98).
Here, triple therapy with MTX, cyclosporine and prednisolone
was more effective at reducing disease activity compared
to MTX monotherapy only in ACPA-positive early RA
patients.
Based on the above described evidences, it would be tempting
to speculate that, by interfering with both the innate and the
adaptive branches of the immune system (99), MTX at high doses
is particularly effective in autoantibody-positive RA. However,
one cannot exclude that the observed differences are actually
related to misdiagnoses in patients lacking autoantibodies, rather
than to intrinsic pathogenetic pathways differentially susceptible
to different treatment strategies.
Response to Biological DMARDs
If the differential response to csDMARDs according to the
autoantibody profile remains questionable, the impact of the
serological status on response to biological (b) DMARDs
targeting different immune pathways is, at least for certain
mechanisms of actions, more defined.
It can be easily appreciated that bDMARDs selectively
affecting the process of autoantibody production, including B cell
depletion or inhibition of T cell costimulation, are particularly
effective in autoantibody-positive patients. A meta-analysis of
four randomized placebo-controlled trials from the rituximab
clinical programme confirmed the additional treatment benefit
in autoantibody-positive RA, particularly in patients for whom
at least one TNF inhibitor had failed, and without significant
differences between RF and ACPA (100). Similarly, a meta-
analysis of 23 clinical trials and observational studies showed
that positivity for RF at baseline predicted better response
to rituximab according to both the ACR and the EULAR
criteria (101). In recent times, ACPA positivity has emerged
as particularly relevant in affecting the response to inhibition
of T cell co-stimulation. A post-hoc analysis of the AMPLE
trial in 2016 initially showed that very high levels of ACPA at
baseline were associated with better clinical response to abatacept
but not to adalimumamb (102). Such association has found
confirmation in several independent real-life studies. In the
French ORA registry, the proportion of ACPA-positivity was
significantly higher among EULAR responders at 6 months
(103). Data from other registries and real-world studies, such
as the PanEuropean registry and the ACTION study, have
shown that baseline autoantibodies impact on the retention
rate of abatacept, as a surrogate marker of efficacy and safety
(104, 105). Again, RF and ACPA appear both associated with
better efficacy and lower risk of abatacept discontinuation
for any reason (105, 106). It is also interesting to note
that both B cell depleting agents and co-stimulation blockade
selectively and equally affect not only RF, but also ACPA
levels, thus confirming direct interference with adaptive immune
responses (107). Although the clinical meaning of reduced
ACPA titres upon treatment remains to be determined, initial
evidence is starting to suggest that conversion to seronegative
status may be associated with better clinical and radiographic
outcomes (108).
Studies on the prognostic value of autoantibodies for response
to therapy to bDMARDs targeting different mechanisms of
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FIGURE 2 | The possible value of autoantibodies as biomarkers in rheumatoid
arthritis. The graph represents the possible trajectories of disease activity over
time in patients with rheumatoid arthritis (RA): persistently high disease activity
despite methotrexate (MTX) treatment (blue); satisfactory control of disease
activity with a disease activity score indicative of low disease (red);
achievement of remission, which is however unstable at follow-up (green);
achievement of sustained remission (purple). Accurate prediction of such
trajectories in every patient is currently an unmet need. The analysis of the fine
characteristics of the autoantibody response in course of RA, including
autoantibody levels, avidity, classes, subclasses and biochemical properties
might generate useful biomarkers capable of answering critical questions such
as: (Q1) the identification of those patients more likely to respond to first-line
treatment with methotrexate (MTX); (Q2) the choice of second-line drug,
among several mechanisms of actions available, in MTX-failures; (Q3) the
possibility of tapering/stopping medications in patients achieving remission.
action are less conclusive. The assessment of response to TNF
inhibitors according to RF and/or ACPA status has provided
conflicting results. A systematic literature review of 14 studies
involving more than 5,000 patients treated with infliximab,
etanercept, adalimumab, and golimumab demonstrated that
neither RF nor ACPA were associated with differential response
(109). However, the heterogeneity of the analysis was high,
leaving results largely uncertain. Some studies have indeed
highlighted lower rates of response in patients with high levels
of RF (24, 110), particularly of the IgA class (24). These
results have very recently been confirmed by post-hoc analyses
on the RISING study, in which the dose of infliximab was
progressively escalated (111, 112). In this study, patients with
levels of RF and ACPA both high were characterized by higher
levels of TNF, lower levels of infliximab and lower clinical
response. Tociluzumab has even more discordant data. Indeed,
response to IL-6 targeting does not seem to be affected by
the ACPA status (113, 114). In contrast, high levels of RF
would appear to favor tociluzimab treatment according to
one report (114) and one meta-analysis (101). However, the
mechanism of action of IL-6 antagonism in RA is complex and
includes interference with both the innate and adaptive arms
of the immune system. Accordingly, blockade of IL-6 receptor
suppresses T- and B-cell activation signatures in RA synovium
similarly to rituximab, but differently from TNF-antagonists
(115). It is therefore very likely that those patients with the
highest levels of activation of the B cell compartment also show
preferential response to IL-6 targeting. In line with this concept,
RA patients showing dense infiltration of lymphoid cells in their
synovial membrane, as well as elevated serum levels of factors
involved in B cell recirculation and positioning (such as the
chemokine CXCL13), respond to tociluzumab better than to
adalimumamb (116).
CONCLUSIONS
Given the complex pathophysiology and the clinical
heterogeneity of RA, biomarkers capable of guiding personalized
treatment approaches are urgently needed. RA would indeed
benefit from personalized approaches across all the phases
of disease development and evolution (Figure 2). Prompt
recognition of at risk subject would indeed pave the way for
preventive strategies. Soon after disease diagnosis, the precise
identification of those patients in whom conventional, less
expensive, and safe drugs such as MTX are more likely to be
effective would allow significant savings for individuals and
the society as a whole. Also, a more detailed and informed
understanding of the phase of clinical remission would improve
our ability to tailor treatment and follow-up to the individual
patient. Several lines of evidence indeed indicate that, once
remission has been achieved, the decision of tapering therapies
is largely empirical, with high rates of insuccess. While awaiting
new prognostic markers, rheumatologist may still obtain valuable
information from traditional factors including autoantibodies.
At present, neither RF nor ACPA can be reliably used as absolute
markers of prognosis and response to treatment. However,
the field of immunology is moving fast, and has opened new
perspectives that, in the near future, could have important
clinical translation. We believe that further refinement of the
analytic procedures capable of capturing the broad spectrum
of autoantibody characteristics, including classes, subclasses,
specificities and biochemical properties, will rapidly allow better
subclassification of patients with RA.
BULLET POINTS AND RESEARCH
AGENDA
X The dichotomic classification of patients with RA into
autoantibody-positive and -negative solely based on RF and/or
ACPA appears too simplistic.
X The autoantibody system in RA is likely to expand rapidly
with the identification of new antigenic specificities.
X The pathogenic properties of autoantibodies depend on
several characteristics including levels, avidity, classes,
subclasses, and biochemical properties.
X All of these properties are likely to be modulated in different
patients during different phases of the disease.
X Further studies are needed to test whether the different
characteristics of autoantibodies, alone or in combination,
may serve as biomarkers for:
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• prediction of disease development in at risk individuals
• prediction of response to MTX
• choice of the second-line drug in MTX-failures
• identification of patients in whom remission is more likely to
persist even after drug tapering/discontinuation
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